[{"address1": "177 East Colorado Boulevard", "address2": "Suite 700", "city": "Pasadena", "state": "CA", "zip": "91105", "country": "United States", "phone": "626 304 3400", "fax": "626 304 3401", "website": "https://arrowheadpharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's product pipeline includes Plozasiran, which has completed Phase 3 clinical trial to treat hypertriglyceridemia, dyslipidemia, and familial chylomicronemia syndrome; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; and Fazirsiran that is in Phase 3 clinical trial for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. It also develops Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; GSK-4532990 to treat metabolic-dysfunction associated steatohepatitis (MASH); and Daplusiran/Tomligisiran which is in Phase 2 clinical trial for the treatment of Chronic Hepatitis B. In addition, the company is developing ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with MASH; ARO-INHBE to reduce the hepatic expression of the INHBE gene and its secreted gene product; ARO-RAGE to treat inflammatory lung disease; ARO-MUC5AC to treat muco-obstructive pulmonary diseases; and ARO-MMP7 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1/2a clinical trials. Further, it develops ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-DM1 to treat patient with Type 1 Myotonic Dystrophy; ARO-C3 to treat complement-mediated renal disease; ARO-CFB for the treatment of complement-mediated kidney disease that is in Phase 1/2a clinical trial; and ARO-ATXN2 for the treatment of Spinocerebellar Ataxia Type 2 that is in Phase 1 clinical trial. Arrowhead Pharmaceuticals, Inc. has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Horizon Therapeutics Ireland DAC; Takeda Pharmaceutical Company Limited; and with Amgen Inc. The company was founded in 2003 and is headquartered in Pasadena, California.", "fullTimeEmployees": 609, "companyOfficers": [{"maxAge": 1, "name": "Dr. Christopher R. Anzalone Ph.D.", "age": 55, "title": "Chairman, CEO & President", "yearBorn": 1969, "fiscalYear": 2024, "totalPay": 2104473, "exercisedValue": 1024000, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Patrick  O'Brien J.D., PharmD", "age": 60, "title": "COO, General Counsel & Secretary", "yearBorn": 1964, "fiscalYear": 2024, "totalPay": 998520, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. James C. Hamilton M.D., MBA", "age": 46, "title": "Chief Medical Officer and Head of R&D", "yearBorn": 1978, "fiscalYear": 2024, "totalPay": 897694, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mark M. Davis Ph.D.", "title": "Founder and Founder & Director of Insert Therapeutics Inc & Calando", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Daniel J. Apel", "title": "Chief Financial Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Vincent  Anzalone CFA", "title": "Head of Investor Relations & VP", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Howard  Lovy", "title": "Director of Communications", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Bruce D. Given M.D.", "age": 70, "title": "Chief Medical Scientist", "yearBorn": 1954, "fiscalYear": 2024, "totalPay": 486308, "exercisedValue": 5934362, "unexercisedValue": 6159876}, {"maxAge": 1, "name": "Dr. Mark  Seefeld", "age": 70, "title": "Head of Toxicology & VP", "yearBorn": 1954, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Aaron  Tan", "title": "Head of Tax", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 7, "compensationRisk": 2, "shareHolderRightsRisk": 1, "overallRisk": 2, "governanceEpochDate": 1761955200, "compensationAsOfEpochDate": 1735603200, "irWebsite": "http://www.arrowheadresearch.com/invest.html", "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 41.14, "open": 39.85, "dayLow": 39.33, "dayHigh": 41.785, "regularMarketPreviousClose": 41.14, "regularMarketOpen": 39.85, "regularMarketDayLow": 39.33, "regularMarketDayHigh": 41.785, "payoutRatio": 0.0, "beta": 1.31, "forwardPE": -9.777251, "volume": 1387238, "regularMarketVolume": 1387238, "averageVolume": 2221529, "averageVolume10days": 1647760, "averageDailyVolume10Day": 1647760, "bid": 41.14, "ask": 41.34, "bidSize": 1, "askSize": 1, "marketCap": 5704506368, "fiftyTwoWeekLow": 9.57, "fiftyTwoWeekHigh": 43.69, "allTimeHigh": 2925.0, "allTimeLow": 1.2, "priceToSalesTrailing12Months": 9.955926, "fiftyDayAverage": 35.8478, "twoHundredDayAverage": 21.417725, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 5517113344, "profitMargins": -0.25902998, "floatShares": 119533330, "sharesOutstanding": 138257550, "sharesShort": 11784510, "sharesShortPriorMonth": 11698624, "sharesShortPreviousMonthDate": 1759190400, "dateShortInterest": 1761868800, "sharesPercentSharesOut": 0.085200004, "heldPercentInsiders": 0.04407, "heldPercentInstitutions": 0.80467004, "shortRatio": 6.44, "shortPercentOfFloat": 0.11, "impliedSharesOutstanding": 138257550, "bookValue": 3.781, "priceToBook": 10.9124565, "lastFiscalYearEnd": 1727654400, "nextFiscalYearEnd": 1759190400, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -148416992, "trailingEps": -1.2, "forwardEps": -4.22, "lastSplitFactor": "1:10", "lastSplitDate": 1321488000, "enterpriseToRevenue": 9.629, "enterpriseToEbitda": -64.606, "52WeekChange": 1.1692955, "SandP52WeekChange": 0.14261019, "quoteType": "EQUITY", "currentPrice": 41.26, "targetHighPrice": 80.0, "targetLowPrice": 17.0, "targetMeanPrice": 48.83333, "targetMedianPrice": 45.0, "recommendationMean": 1.84615, "recommendationKey": "buy", "numberOfAnalystOpinions": 12, "totalCash": 898172032, "totalCashPerShare": 6.496, "ebitda": -85396000, "totalDebt": 713286016, "quickRatio": 4.667, "currentRatio": 4.868, "totalRevenue": 572976000, "debtToEquity": 137.222, "revenuePerShare": 4.395, "returnOnAssets": -0.0596, "returnOnEquity": -0.37111, "grossProfits": 572976000, "freeCashflow": -48370124, "operatingCashflow": 21845000, "grossMargins": 1.0, "ebitdaMargins": -0.14904, "operatingMargins": -5.96211, "financialCurrency": "USD", "symbol": "ARWR", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "fiftyTwoWeekChangePercent": 116.92956, "earningsTimestamp": 1764104400, "earningsTimestampStart": 1764104400, "earningsTimestampEnd": 1764104400, "earningsCallTimestampStart": 1764106200, "earningsCallTimestampEnd": 1764106200, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -1.2, "epsForward": -4.22, "epsCurrentYear": -0.08727, "priceEpsCurrentYear": -472.78558, "marketState": "CLOSED", "regularMarketChangePercent": 0.291684, "regularMarketPrice": 41.26, "corporateActions": [], "postMarketTime": 1763166193, "regularMarketTime": 1763154001, "exchange": "NMS", "messageBoardId": "finmb_203142", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "fiftyDayAverageChange": 5.412197, "fiftyDayAverageChangePercent": 0.1509771, "twoHundredDayAverageChange": 19.842274, "twoHundredDayAverageChangePercent": 0.9264417, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.8 - Buy", "cryptoTradeable": false, "shortName": "Arrowhead Pharmaceuticals, Inc.", "longName": "Arrowhead Pharmaceuticals, Inc.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 756052200000, "postMarketChangePercent": 1.6480861, "postMarketPrice": 41.94, "postMarketChange": 0.6800003, "regularMarketChange": 0.119999, "regularMarketDayRange": "39.33 - 41.785", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 2221529, "fiftyTwoWeekLowChange": 31.689999, "fiftyTwoWeekLowChangePercent": 3.3113897, "fiftyTwoWeekRange": "9.57 - 43.69", "fiftyTwoWeekHighChange": -2.4300003, "fiftyTwoWeekHighChangePercent": -0.055619143, "displayName": "Arrowhead Pharmaceuticals", "trailingPegRatio": null, "__fetch_time": "2025-11-15"}]